Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus

Kucharska, Magdalena; Zaleska-Dorobisz, Urszula; Szymczak, Aleksandra; Inglot, Marcin; Rymer, Weronika; Zalewska, Małgorzata; Małyszczak, Krzysztof; Kuliszkiewicz‐Janus, Małgorzata; Inglot, Małgorzata

doi:10.20452/pamw.4027

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that bone mass depends, inter alia, on physical activity, so it should correlate with the efficiency of the joints, but also with the possible fear of trauma and bleeding, which may occur in patients with congenital bleeding diathesis [ 20 ]. The literature also suggests that there may be a direct relationship between factor VIII and IX and bone resorption [ 21 , 22 , 23 ], as well as between the development of osteoporosis and infection [ 24 ], which may occur due to the use of blood products [ 25 , 26 ]. In addition, decreased bone density may be associated with vitamin D deficiency [ 27 ] (related to the geographical location and climate of the inhabited region), decreased serum total calcium levels, or be dependent on the level of proinflammatory cytokines.…”

Section: Introductionmentioning

confidence: 99%

The Profile of Markers of Bone Turnover, Inflammation and Extracellular Neutrophil Traps on Bone Mass in Haemophilia and the Development of Haemophilic Arthropathy

Czajkowska

Rupa‐Matysek

Wojtasińska

et al. 2022

JCM

View full text Add to dashboard Cite

Background: The aim of the study is to evaluate selected biomarkers of bone turnover, inflammation, neutrophil trap and factors predisposing haemophiliacs to bone loss, and to analyse their relationship with clinical features, treatment and complications. Methods: The levels of interleukin 6 (IL-6); citrullinated histone (CH3); osteocalcin (BGLAP); bone alkaline phosphatase (BALP); N-terminal procollagen type I propeptide (P1NP); and C-terminal collagen type I telopeptide (C1CP) were examined in 60 patients with haemophilia. Results: The cut-off value for BGLAP is 26.41 ng/mL, and 929.7 pg/mL for CH3. There is a statistically significant difference between BGLAP, BALP, C1CP and CH3 concentrations, depending on the prophylaxis used. The median concentration of BGLAP in patients taking the factor on demand is 28.0 ng/mL, BALP 322.5 U/L, C1CP 191.2 ng/mL and CH3 1114.4 pg/mL. In patients taking recombinant coagulation factor VIII/IX as prophylaxis of bleeding, the median BGLAP concentrations are 35.9 ng/mL, BALP 280.9 U/L, C1CP 161.6 ng/mL and CH3 952.5 pg/mL. BGLAP and BALP concentrations are dependent on the development of haemophilic arthropathic. Conclusions: The concentrations of selected markers of bone turnover and NETs may help to identify patients at particular risk of developing haemophilic arthropathy and bone metabolic turnover abnormalities.

show abstract

Section: Introductionmentioning

confidence: 99%

The Profile of Markers of Bone Turnover, Inflammation and Extracellular Neutrophil Traps on Bone Mass in Haemophilia and the Development of Haemophilic Arthropathy

Czajkowska

Rupa‐Matysek

Wojtasińska

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Prior to 1990, almost all patients acquired HCV infection; moreover, some of them were also coinfected with human immunodeficiency virus (HIV). Rates of disease progression among patients with congenital bleeding disorders and chronic HCV infection vary; however, the time of infection and coinfection with HIV appear to correlate with more rapid progression [ 8 ]. Antiviral treatment is no different from that of other infected individuals and aims to eradicate HCV and improve liver fibrosis [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management

Papadopoulos¹,

Argiana²,

Deutsch

2017

aog

View full text Add to dashboard Cite

Hereditary bleeding disorders include a group of diseases with abnormalities of coagulation. Prior to 1990, infection with hepatitis C virus (HCV) was mainly transmitted via pooled plasma products as a treatment for hereditary bleeding disorders. Anti-HCV positivity in these patients may be as high as >70% in some areas, while some of them have also been coinfected with human immunodeficiency virus. Since about 20% of HCV-infected patients clear the infection naturally, chronic HCV infection represents a significant health problem in this group of patients. Mortality due to chronic HCV infection is estimated to be >10 times higher in patients with hemophilia than in the general population, and is mainly due to liver cirrhosis and hepatocellular carcinoma. The antiviral treatment of HCV in patients with hereditary bleeding disorders is not different from that of any other infected patients. Nevertheless, many patients with hereditary bleeding disorders have declined (Peg)interferon-based treatment because of side effects. In recent years, multiple orally administrated direct-acting antivirals (DAAs) have been approved for HCV treatment. Unfortunately, there is not much experience from treating these patients with DAA regimens, as major studies and real-life data did not include adequate numbers of patients with inherited hemorrhagic disorders. However, the available data indicate that DAAs have an excellent safety profile with a sustained virological response rate of >90%.

show abstract

“…Dynamics of progression of chronic liver disease depends on many factors: age, sex, HCV genotype, inflammation activity, mixed infection of hepatitis B virus (HBV) or human immunodeficiency virus (HIV), other infections associated with blood transfusion, presence of metabolic disorders (diabetes, obesity, fatty hepatosis, increased concentration of iron in serum), and smoking [17,18,19,20]; in general, this comorbid pathology affects psychosomatic features and quality of life of these patients [21,22,23,24].…”

mentioning

confidence: 99%

Parenteral Viral Hepatitis in People With Hemophilia: Ways to Solve the Problem

Nikonorova

Карбышева

Кожевникова

et al. 2019

Bulletin of Medical Science

View full text Add to dashboard Cite

Clinical and laboratory examination of 80 patients with hemophilia aged 16-59 living in the Altai Krai was carried out. From childhood, all patients have repeatedly received cryoprecipitate or fresh frozen plasma. In 50 of 80 patients with hemophilia (62.5%), chronic viral hepatitis (CVH) was diagnosed: CVH B and C in 1 patient (2%), CVH B in 2 (4%) and CVH C in 47 patients (94%). The mean age of patients with hemophilia and CVH is 38.4 (22-59 years). All patients have no data on the prior acute hepatitis B or C. In 30%, we noted an increase of ALT (in 30%), AST (in 20.4%), GGT (in 26.6%), ALP (in 13.3%). The obtained biochemical data indicate the presence of a minimal degree of activity of chronic hepatitis.

show abstract

Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus

Cited by 3 publications

References 10 publications

The Profile of Markers of Bone Turnover, Inflammation and Extracellular Neutrophil Traps on Bone Mass in Haemophilia and the Development of Haemophilic Arthropathy

The Profile of Markers of Bone Turnover, Inflammation and Extracellular Neutrophil Traps on Bone Mass in Haemophilia and the Development of Haemophilic Arthropathy

Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management

Parenteral Viral Hepatitis in People With Hemophilia: Ways to Solve the Problem

Contact Info

Product

Resources

About